Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues
Executive Summary
Wyeth's approval of lower-dose Prempro gives the company a positive marketing message to counter the safety concerns raised by the Women's Health Initiative hormone replacement therapy study findings
You may also be interested in...
Wyeth Prempro DTC
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...
Wyeth Prempro DTC
Wyeth expects to have DTC advertisements within the next several months to promote a lower dose of its hormone replacement therapy Prempro (.45 mg conjugated estrogens/1.5 mg medroxyprogesterone), which was launched July 1 after gaining FDA approval March 12 (1"The Pink Sheet" March 17, 2003, p. 4). Prempro .45 mg/1.5 mg is the middle dosing option in the Prempro franchise following the approval of the Prempro .3 mg/1.5 mg dose June 4 (2"The Pink Sheet" June 16, 2003, p. 35)...
Prempro Low(er) Clears FDA: .3 mg/1.5 mg Is Start Dose For Osteoporosis
Wyeth's Prempro osteoporosis prevention treatment should begin with .3 mg conjugated estrogens/1.5 mg medroxyprogesterone following FDA approval of the lowest dose of the hormone therapy June 4